Social support, perceived stigma, and depression among PLHIV on second-line antiretroviral therapy using structural equation modeling in a multicenter study in Northeast Ethiopia

Shambel Wedajo1*, Getu Degu2, Amare Deribew3 and Fentie Ambaw2

Abstract

Background: Depression has a multitude of clinical and public health consequences for HIV patients. The magnitude of HIV patients who failed first-line antiretroviral treatment and switched to second-line therapy is becoming a growing public health concern. However, unlike first-line therapy, to date, little attention has been given to mental health problems in such patients, particularly in the era of the COVID-19 pandemic. Thus, this research was conducted to determine the magnitude of depression and its determinants among HIV patients on second-line antiretroviral therapy.

Methods: A multi-centered cross-sectional study was conducted on 714 HIV patients on second-line therapy who were selected via systematic random sampling. Data were collected in personal interviews as well as document reviews. The nine-item patient health questionnaire score was used to assess depression, while the three-item Oslo Scale was used to assess social support. The associations between exogenous, mediating, and endogenous variables were identified simultaneously using structural equation modeling. Statistical significance was declared at a P-value less than 0.05, and the effect sizes were presented using 95% CI.

Results: Depression was reported in 27.7% of HIV patients on second-line therapy [95% CI: 24.7–31.1%]. Social support has a direct [\( \hat{\beta} = -0.9, (95\% \text{ CI}: -1.11 \text{ to } -0.69) \)] and indirect [\( \hat{\beta} = -0.22, (95\% \text{ CI}: -0.31 \text{ to } -0.13) \)] negative effect on depression. Perceived stigma was a mediator variable and significantly associated with depression [\( \hat{\beta} = 0.40, (95\% \text{ CI}: 0.23 \text{ to } 0.57) \)]. Co-morbid illness [\( \hat{\beta} = 0.49, (95\% \text{ CI}: 0.35 \text{ to } 0.63) \)], high viremia [\( \hat{\beta} = 0.17, (95\% \text{ CI}: 0.08 \text{ to } 0.26) \)], moderate and high-risk substance use [\( \hat{\beta} = 0.29, (95\% \text{ CI}: 0.18 \text{ to } 0.39) \)], and not-workable functional status [\( \hat{\beta} = 0.2, (95\% \text{ CI}: 0.1 \text{ to } 0.31) \)] were all positively associated with depression.

Conclusions: This study revealed that there was a high prevalence of depression among HIV patients on second-line antiretroviral therapy. Social and clinical factors were associated with depression risk. As a result, screening, prevention, and control strategies, including psychosocial support, should be strengthened in routine clinical care.

Keywords: Social support, Depression, Stigma, SEM, HIV/AIDS, Second-line ART

*Correspondence: Swedajo@gmail.com

1 School of Public Health, CMHS, Wollo University, Dessie, Ethiopia

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction

Globally, 27.5 million people living with HIV (PLHIV) have accessed antiretroviral therapy (ART) by the end of 2020 [1]. However, currently, the magnitude of HIV patients on second-line antiretroviral therapy is becoming a growing public health concern. A considerable number of patients worldwide had experienced first-line treatment failure and switched to second-line antiretroviral treatment [2]. In Ethiopia, the proportion of people living with HIV on second-line antiretroviral therapy is also a rising issue; according to a systematic review, 15.9% (11.6–20.1%) of PLHIV had failed their first-line regimen [3]. Treatment failure is characterized by a worsening of HIV clinical symptoms while on antiretroviral treatment, and those patients will be switched to second-line antiretroviral therapy [4].

PLHIVs are disproportionately affected by mental health problems [5]. “Depression is a common mental health problem characterized by sadness, loss of interest or pleasure, feelings of guilt or low self-worth, disturbed sleep or appetite, feelings of tiredness, and poor concentration” [6]. According to the Ethiopian national health survey, the prevalence of depression in the general population was 9.1% (95CI%; 8.39–9.9%) [7]. In contrast, a systematic review conducted in Ethiopia revealed that the pooled prevalence rate of depression in PLHIV on first-line antiretroviral was 36.65% (25.48, 47.82%) [8]. Furthermore, in the era of the COVID-19 pandemic, PLHIVs not only have a higher risk of severe illness [9], but they also may have an increased risk of depression, which is associated with stress, social isolation, and stigma [10].

Depression and HIV infection have a bidirectional relationship [4]. Depression can result in worsening HIV-related treatment outcomes and compromise the overall quality of life, including poor medication adherence, immunological failure, and the development of severe opportunistic infection. Consequently, increase the chance of subsequent treatment failure and the development of drug-resistant strains. Depression can also raise the likelihood of substance abuse and other high-risk behaviors including the risk of HIV acquisition [11]. Similarly, HIV infection causes depression as a result of coping with the diagnosis, worsening clinical symptoms, stigma, social rejection, co-existing poverty, and the adverse effects of certain antiretroviral medications [4].

Even though HIV and depression are linked, very little is known about the magnitude of depression among HIV patients who were receiving second-line antiretroviral therapy, especially during the COVID-19 pandemic. Besides, some symptoms of depression and HIV are mimicked; consequently, depression in PLHIV might be under-recognized and under-treated.

The risk factors for depressive symptoms are interconnected, and most previous studies have used the univariate analysis method to address these issues. However, this method of analysis has limitations in terms of identifying the direct and indirect effects of covariates, as well as failing to account for measurement errors for latent constructs such as depression, social support, and internal and perceived stigma. Furthermore, factors which lead to depressive symptoms are heterogeneous, and local evidence is required for context-based decision making and intervention during the COVID-19 pandemic. Social distancing and other mitigation strategies in the prevention of COVID-19 have a considerable effect on social support and mental health problems [12]. To mitigate COVID-19, HIV, and mental health issues, it is necessary to generate cultural and context-based evidence.

Hence, based on the above-identified gaps, we conducted a multi-centered cross-sectional study to determine the magnitude of depression and to investigate the association between depression symptoms and socio-demographic, clinical, social support, and internal and perceived stigma among PLHIV on second-second antiretroviral therapy. To investigate such factors, the Structural Equation Model (SEM) was employed.

Methods

Study setting

This study was conducted in twenty public health facilities that currently provide second-line therapy in the eastern Amhara region, northeast Ethiopia. Of those facilities, six were hospitals, and fourteen were health centers. According to Ethiopia’s national HIV/AIDS guideline, health centers having greater than 200 HIV patient loads are allowed to initiate second-line treatment. Eastern Amhara is a high-burden area in the region [13, 14]. Currently, 2332 PLHIV are attending the second-line program in the above health facilities.

In Ethiopia, the current standard second-line antiretroviral therapy consists of a combination of three ARV drugs (at least two of which are new to the patient); two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) as a backbone; Lamivudine (3TC) and Abacavir (ABC), or Zidovudine (ZDV) or Tenofovir (TDF) and one protease Inhibitors (Pis); Lopinavir/ ritonavir (LPV/r) or Atazanavir /ritonavir (ATV/r) [4, 15]. Those Pis drugs are safer, more effective in viral suppression, and have a lower risk of resistance [16, 17].

Moreover, all facilities use the same documentation and reporting system, and HIV data are handled by SMART care, ART registration/logbook/, and chronic ART follow-up form [15]. At every clinical visit, these registers are updated. PLHIV is currently scheduled every 3 months. Patients will be assessed for nutritional status,
opportunities for infections, medication adherence, drug side effects, and refilled with ART and other preventative medications at each appointment. Antiretroviral treatment success is monitored using clinical, immunological, and viral load (VL) assessment, in which viral a load test is done after initiation of ART at 6 months, 12 months, and every 12 months and serves as a gold standard monitoring tool [4, 15].

**Study design and period**

A multi-centered cross-sectional study was conducted in the Eastern Amhara region, Northeast Ethiopia, from December 2020–to February 2021.

**Source and study population**

HIV patients who were receiving second-line antiretroviral therapy and following their HIV care and treatment in the eastern Amhara region were considered a source population, whereas those who were available during the data collection period were considered a study population.

**Variables and measurements**

The primary outcome variable in this study was depression, which was measured using the nine-item Patient Health Questionnaire (PHQ-9) [18]. Each question requires participants to rate the frequency of a depressive symptom experienced in the two weeks before evaluation. The total score ranges from 0 to 27. The severity of depression symptoms was divided into five categories: not depressed (0 points), mild depression (5–9 points), moderate depression (10–14 points), moderately severe depression (15–19 points), and severe depression (20–27 points). To determine the prevalence of clinical depression, patients having depression scores of ten or above were considered as having clinical depression. This PHQ-9 items depression screening tool was validated in the Ethiopian context [19].

Perceived and internalized stigma were measured by six and eight items on the HIV Stigma Scale [20, 21]. Items were evaluated using a four-point Likert scale (strongly disagree, disagree, agree, and strongly agree), with higher scores indicating higher levels of stigma. The total score of the scale for PS and IS ranged from 6–24 and 8–32, respectively.

In this study, social support is expected to have a direct and indirect effect on depression, which was measured using the three-item Oslo Scale [22]. The Oslo Scale’s total score ranges from 3 to 14, with the higher value indicating strong social support. For descriptive purposes, the social support scale was divided into three broad categories: "poor support" (3–8), "moderate support" (9–11), and "strong support" (12–14). For SEM analysis, the row social support score was used as a continuous scale.

The risk of substance use was measured using the WHO Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) (V.3.1), which consists of seven items for each of alcohol, khat use, and tobacco products [23]. Participants were then classified as having low, moderate, or high-risk substance use depending on their score.

The socio-demographic characteristics include age, sex, marital status, education level, independent source of income, and substance use. Similarly, the following patient clinical characteristics were included: Body mass index (BMI), functional status, WHO-clinical stage, viral load, medication adherence, and comorbidity (Fig. 1). An individual's comorbidity status was assessed using a self-report method. Co-morbid NCDs are defined as a patient who has one or more of the following confirmed non-communicable illnesses (NCDs): diabetes, cardiovascular disease, hypertension, and cancer. Medication adherence was assessed using a self-report method taken from the patient's medical records. Patients who were taking 95% of the prescribed antiretroviral medication were considered to have optimal adherence unless classified as not having optimal medication adherence [15]. Patients with viral load measurements below 1000 copies/mL are considered as low viremia unless they have been classified as having high viral load (high viremia) [4]. Two criteria were used to classify CD4 cells. Healthy individual CD4 cell counts range from 450 to 1500. The risk of opportunistic infection begins in HIV patients when CD4 cell counts are less than 450. Hence, based on the above two concepts, 450 cells/mm3 was used to categorize the last CD4 cell measurement [4, 15].

**Sample size**

The basic rule of thumb for determining the minimum required sample size for structural equation modeling is 5 to 20 times the number of free parameters to be estimated in the hypothesized model [24]. A 1:10 ratio of free parameters to be estimated to respondents was used to calculate the required sample size to meet the study’s objectives. This implies that there should be ten respondents for each free parameter in the hypothesized model. As a result, the required sample size was determined to be 670, based on the 67 parameters to be estimated based on the postulated model (Fig. 1). The final sample size, after adding 10% for non-response, was computed as 737.

**Sampling procedure**

A systematic random sampling method was used to select the sample individuals. First, the sampling frame was secured in each facility by reviewing the updated
ART registration logbook. Then, based on the number of patient loads, samples were proportionally allocated to each health facility. Finally, using the systematic random sampling method, sample clients were recruited every third interval while the clients came for routine follow-up.

Data collection
Data were collected using a structured questionnaire via face-to-face interviews by trained degree nurses at the ART outpatient department (ART-OPD). A questionnaire was prepared in the local language and data were collected for a three-month duration while the patient came for a routine clinical visit. Moreover, document reviews are also done to extract patient clinical profiles. The extraction sheet was prepared per the national consolidated antiretroviral guidelines [15].

Data quality management
To ensure the quality of the data, the questionnaire was prepared by considering existing literature and guidelines. Furthermore, validated tools were used to measure latent constructs. The questionnaire was also pretested, and necessary modifications were made. Data collectors were trained on the objective of the study, the content of the questionnaire, and, in general, how to collect the required data. The data collection procedures were closely supervised, and on-site feedback was given.

Data analysis
Data were cleaned and entered into the EpiData Version 3.1 software. Then, exported to Stata version 14 for further analysis. For categorical variables, frequency (%) was computed. For a continuous variable, first, distributional assumptions were checked using the Kolmogorov–Smirnov and Shapiro–Wilk test. Then, for normally and skewed distributed continuous variables, mean with standard deviation (SD) and median (interquartile range, IQR) were employed, respectively.

The hypothesized association between various exogenous and endogenous or mediating variables was verified using the Structural Equation Model (SEM). The effect size was presented using standardized and unstandardized beta coefficients, and statistical significance was declared at a P-value less than 0.05. The analysis began with the hypothesized model (Fig. 1), and modifications were made iteratively by comparing model fit indices and information criteria of each model fitted, then adding

Fig. 1 A hypothesized model for factors associated with depression among people living with HIV on second-line antiretroviral therapy (oval and rectangular shape variables represent latent and observed variables, respectively).
path links or including mediator variables if the path coefficient is statistically significant and theoretically supported. Finally, an over-identified model with the best model fit indices and the smallest amount of information was kept (Fig. 1). The direct, indirect, and total effects were calculated using a nonlinear combination of estimator techniques when the mediation effect was present.

**Results**

**Socio-demographic characteristics**

Out of 737 approached sample patients, 714 (96.87%) agreed and gave their consent to participate in this study. Of those surveyed, 468 (65.5%) lived in urban areas, 400 (56%) were female, and 342 (47.9%) were married. Concerning the source of income, 511 (71.6%) participants had an independent source of income. Similarly, of the 714 participants, 281 (39.4%) had not attained formal education, and 355 (49.7%) were orthodox religious followers. The median (IQR) age and year on antiretroviral therapy of participants were 37 (30–45) years and 10 (8–13) years, respectively (Table 1).

**Clinical characteristics**

Out of 714 study participants, 545 (76.3%) had a BMI of \( \geq 18.5 \) kg/m\(^2\), while 540 (75.6%) participants had viral load measurements below 1000 copies/ml. Similarly, 685 (95.9%) and 608 (85.2%) participants were not in advance of the WHO clinical stage and workable functional status, respectively. Regarding medication adherence and comorbidity status, 679 (95.1%) patients had optimal adherence and 63 (8.8%) patients had a comorbid disease. TDF-3TC-ATV/r (361 (50.6%)) and AZT-3TC-ATV/r (338 (47.3%)) were the most prescribed second-line antiretroviral regimens (Table 2).

| Table 1 | Socio-demographic characteristics of PLHIV on second-line antiretroviral therapy in the Eastern Amhara region, Northeast Ethiopia, December 2020–February 2021 (n = 714) |
|---------|---------------------------------------------------------------------------------------------------------------|
| **Socio-demographic characteristics** | **Total (714)** | **Depression (198)** |
| | N (%) | N (%) |
| Sex | | |
| Female | 400 (56) | 122 (30.5) |
| Male | 314 (44) | 76 (24.2) |
| Residence | | |
| Urban | 468 (65.5) | 122 (26.1) |
| Rural | 246 (34.5) | 76 (30.9) |
| Marital status | | |
| Married | 342 (47.9) | 78 (22.8) |
| Single | 149 (20.9) | 52 (34.9) |
| Divorce | 142 (19.9) | 53 (37.3) |
| Widowed | 81 (11.3) | 15 (18.5) |
| Religion | | |
| Orthodox | 355 (49.7) | 102 (27.8) |
| Muslim | 346 (48.5) | 93 (26.9) |
| Protestant | 10 (1.4) | 2 (20) |
| Catholic | 3 (0.4) | 1 (33.3) |
| Educational level | | |
| Not formally educated | 281 (39.4) | 79 (28.1) |
| Primary school (Grade 1–8) | 268 (37.5) | 69 (25.7) |
| Secondary school (9–12) | 109 (15.3) | 28 (25.7) |
| Above 12 grade (12+ grade) | 56 (7.8) | 22 (39.3) |
| Independent source of income | | |
| Yes | 511 (71.6) | 122 (23.9) |
| No | 203 (28.4) | 76 (37.4) |
| Risk of substance use | | |
| Low-risk substance use | 574 (80.4) | 109 (19.0) |
| Moderate and high-risk substance use | 140 (19.6) | 89 (63.6) |
| Age, median (IQR) (year) | 37 (30–45) | 32 (27–44.5) |
| Year on antiretroviral therapy, median (IQR) (year) | 10 (8–13) | 10 (7–12) |
Depression, social support, and stigma measurement

The prevalence of clinical depression among HIV patients on second-line therapy was 27.7% (95% CI 24.7–31.1%). Out of 714 participants, 47.1% (336) had no signs of depression, while 25.2%, 19.9%, 5.7%, and 2.1% of patients had mild, moderate, moderately severe, and severe signs of depression, respectively. Concerning social support, 24.8% (177), 51.3% (366), and 23.9% (171) of participants had poor, moderate, and strong social support, respectively. The mean (±SD) perceived stigma score of participants was 11.2 ± 4.1. The mean (±SD) internal stigma score of participants was 14.2 ± 4.2.

Correlations between depression, social support, perceived stigma, and other covariates

The relation between depression with social support and perceived stigma was statistically significant with Pearson correlation coefficient (r) measurement (r = −0.63, P-value < 0.001) and (r = 0.57, P-value < 0.001), respectively. Social support was negatively correlated with perceived stigma (r = −0.48, P-value < 0.001) (Table 3).

Measurement model

Confirmatory Factor Analysis (CFA) revealed that all the factor loadings for latent variables were statistically significant at a P-value less than 0.001. Furthermore, an evaluation of model fitness was made. It revealed that the final model was a good fit at Root Mean Square Error of Approximation (RMSEA) = 0.07, Standardized root mean square residual (SRMR) = 0.04, and a Comparative Fit Index (CFI) = 0.93 value (Fig. 2).

Factors associated with depression (direct and indirect effects)

Social support has a direct and indirect negative effect on depression. The direct effect of social support was that as a patient’s social support score increased by one unit, their depression score fell by 0.90 factor on average while holding the effect of other covariates in the model constant [\( \hat{\beta} = -0.9 \), (95% CI: −1.11 to −0.69)]. Furthermore, perceived stigma moderated the effect of social support on depression [\( \hat{\beta} = -0.22 \), (95% CI: −0.31 to −0.13)].

Table 2 Clinical characteristics of PLHIV on second-line antiretroviral therapy in the Eastern Amhara region, Northeast Ethiopia, December 2020–February 2021 (n = 714)

| Clinical characteristics | Total (714) N (%) | Depression (198) N (%) |
|--------------------------|------------------|----------------------|
| BMI > = 18.5 kg/m²²      | 545 (76.3)          | 146 (26.8)          |
| < 18.5 kg/m²²            | 169 (23.7)          | 52 (30.8)           |
| Functional status        |                  |                     |
| Workable                 | 608 (85.2)         | 134 (22.0)          |
| Not workable             | 106 (14.8)         | 64 (60.4)           |
| WHO clinical stage       |                  |                     |
| I and II                 | 685 (95.9)         | 179 (26.1)          |
| III and IV               | 29 (4.1)           | 19 (65.5)           |
| Last HIV viral load measurement |                   |                     |
| High viremia             | 540 (75.6)         | 110 (20.4)          |
| Low viremia              | 174 (24.4)         | 88 (50.6)           |
| Last CD4 cells measurement |                |                     |
| < = 450 cell/mm³         | 603 (84.5)         | 174 (28.9)          |
| > 450 cell/mm³           | 111 (15.5)         | 24 (21.6)           |
| Medication adherence     |                  |                     |
| Optimal adherence        | 679 (95.1)         | 174 (25.6)          |
| Not optimal adherence    | 35 (4.9)           | 24 (68.6)           |
| Comorbidity status       |                  |                     |
| No                       | 651 (91.2)         | 156 (24.0)          |
| Yes                      | 63 (8.8)           | 42 (66.7)           |
| Second-line ART          |                  |                     |
| TDF-3TC-ATV/r            | 361 (50.6)         | 91 (25.2)           |
| AZT-3TC-ATV/r            | 338 (47.3)         | 100 (29.6)          |
| TDF-3TC-LPV/r            | 11 (1.5)           | 6 (54.5)            |
| AZT-3TC-LPV/r            | 4 (0.6)            | 1 (25)              |

Table 3 Correlation between depression, social support, perceived stigma, and other covariates

| Depression (Dep) | Social support (SS) | Perceived stigma (PS) | Functional status (Fun) | High viremia (VL-sup) | Comorbidity (CoM) | Substance use (Sub-use) |
|------------------|---------------------|-----------------------|------------------------|-----------------------|-------------------|------------------------|
| Depression (Dep) | 1                   |                       |                        |                       |                   |                        |
| SS               | −0.6268             | 1                     |                        |                       |                   |                        |
| PS               | 0.5737              | −0.4808               | 1                      |                       |                   |                        |
| Fun              | 0.3271              | −0.2146               | 0.281                  | 1                     |                   |                        |
| VL-sub           | 0.3132              | −0.2793               | 0.2395                 | 0.1942                | 1                 |                        |
| CoM              | 0.2973              | −0.1411               | 0.1629                 | 0.0784                | 0.0534            | 1                      |
| Sub-use          | 0.3998              | −0.3065               | 0.3178                 | 0.2700                | 0.1716            | 0.0329                 |
−0.13). Overall, with one unit increase in social support score, on average depression symptom score fell by 1.12 factors, while all other variables in the model remained constant [$\hat{\beta} = -1.12$ (95% CI: $-1.34$ to $-0.90$)].

Similarly, as the patient-perceived stigma score increased by one unit, the average depression symptom score increased by 0.40, while holding the effect of other covariates in the model constant [$\hat{\beta} = 0.40$, (95% CI: $0.23$–$0.57$)].

Patients with a non-workable functional status had a 0.2 higher average depressive symptom score than those with a workable functional status [$\hat{\beta} = 0.2$, (95% CI: $0.1$–$0.31$)]. Patients with a high HIV viral load and those who had comorbid disease had an average depression score of 0.17 and 0.49 points higher than their counterparts, respectively. Patients at moderate and severe risk of substance use have a 0.29 higher risk of depression than low-risk patients [$\hat{\beta} = 0.29$, (95% CI: $0.18$–$0.39$)] (Table 4).

**Discussion**

The purpose of this study was to determine the magnitude of depression and its determinants among PLHIV on second-line antiretroviral therapy. And found that more than one in four HIV patients had experienced clinically significant depression. Poor social support, high perceived stigma, comorbidities, substance use, uncontrolled viremia, and non-workable functional status were factors significantly associated with depression.

The prevalence rate of clinically significant depression in this study was 27.7%. This finding is higher than Ethiopia’s national health survey depression prevalence rate (9.1%), which was conducted on the general population [7] as well as other studies done on HIV patients [25–27]. In contrast, the finding of this study is lower than some other studies [28–32]. This variation could be due to the difference in depression screening tools used in different research. Besides, socio-demographic and cultural variation might have a role in the variability of depression prevalence from place to place. In general, this finding confirms that a considerable number of HIV patients are affected by depression. This may have multi-face implications at the individual, public, and policy levels. Hence, screening, prevention, and control strategies including psychosocial support should be strengthened in routine HIV clinical care by integrating with WHO’s mental health Gap Action Programme (mhGAP) [33].
The likelihood of depression was found to be negatively related to social support. This association is supported by many studies [8, 31, 34]. Perceived stigma, on the other hand, was positively correlated with depression, which is consistent with prior research findings [8, 21, 31]. Patients who receive social support from family, friends, and other concerned individuals can develop a stronger sense of self-worth [35], gain strength and courage, and feel safe and supported during their illness [36]. Social support also improves medication adherence [37–39], clinical outcomes, and reduces HIV/AIDS stigma [38], all of which may reduce the risk of depression. Furthermore, social support reduces stress, fear, and the risk of depression associated with COVID-19 [40–42]. Generally, this study implies that social support plays a pivotal role in averting mental health problems. Hence, support from family and friends should be encouraged at the societal level while keeping COVID mitigation strategies.

Being non-workable functional status and being comorbid with non-communicable diseases (NCDs) were positively associated with the risk of depression. This finding is consistent with the findings of other studies [25, 32]. Prior literature showed that a significant number of PLHIV had developed non-communicable diseases such as cardiovascular disease, diabetes mellitus, and cancer [43, 44]. Co-occurrence of NCDs in people living with HIV increases pill burden, worsens chronic pain, impaired diet, and disrupts sleep patterns. This also further increases the risk of depression and other mental health problems. Moreover, being unproductive and dependent on others in daily living aggravates the occurrence of depression. Hence, NCD intervention packages should be integrated and delivered with chronic HIV care at the ART clinic.

Uncontrolled viremia and the risk of depression were also positively correlated, which is supported by other studies [45, 46]. When viremia is uncontrolled while on second-line antiretroviral therapy, patients may be concerned about developing drug resistance, treatment failure, and clinical worsening. As a result, depression and other mental health concerns will become more common. Thus, patient-centered psychological counseling, routine viral load monitoring, and enhanced adherence support should be strengthened for high viral load patients.

Substance use was linked to an increased risk of depression, which is supported in prior studies [7, 26, 47]. Patients on second-line antiretroviral therapy may experience psychological stress, particularly during the COVID-19 pandemic, and substance use might provide temporary relief from mental distress. Substance abuse, on the other hand, leads to depression and other mental health issues over time [48, 49]. Depression, in turn, may increase the chance of substance use. This finding suggests that screening for risk of substance use should be promoted in routine HIV clinical care to reduce the burden of depression in HIV patients.

### Strength of the study

First, the study is the first of its kind in Ethiopia to provide first-hand information to improve depression in HIV patients on second-line therapy. Second, this study

| Covariates                                      | Estimates ($\hat{\beta}$) | Standardized estimate | SE of $\hat{\beta}$ | 95% CI       |
|------------------------------------------------|---------------------------|-----------------------|---------------------|--------------|
| Social support $\rightarrow$ depression         | $-0.90$                   | $-0.58$               | 0.11                | $-1.11$ to $-0.69$ |
| Social support $\rightarrow$ perceived stigma  | $-0.54$                   | $-0.6$                | 0.07                | $-0.66$ to $-0.41$ |
| Perceived stigma $\rightarrow$ depression      | $0.40$                    | 0.24                  | 0.09                | 0.23–0.57    |
| An indirect effect of social support            |                           |                       |                     |              |
| $SS \rightarrow PS \rightarrow$ depression    | $-0.22$                   | $-0.14$               | 0.05                | $-0.31$ to $-0.13$ |
| The total effect of social support              | $-1.12$                   | $-0.72$               | 0.11                | $-1.34$ to $-0.90$ |
| Other covariate effects on depression           |                           |                       |                     |              |
| Functional status: not workable                 | 0.2                       | 0.11                  | 0.06                | 0.1–0.31     |
| Comorbidity status: being comorbid              | 0.49                      | 0.22                  | 0.07                | 0.35–0.63    |
| Last HIV viral load measurement                 |                           |                       |                     |              |
| High viremia (VL $> 1000$ copies/ml)           | 0.17                      | 0.11                  | 0.05                | 0.08–0.26    |
| Risk of substance use                           |                           |                       |                     |              |
| Moderate and severe risk of substance use       | 0.29                      | 0.18                  | 0.05                | 0.18–0.39    |
examines the direct, and indirect effects of covariates using SEM analysis while controlling measurement errors for latent variables. Third, it was conducted with large sample size and considered social and clinical variables simultaneously. Lastly, the findings of this study can be generalized to other low-income areas where similar WHO HIV treatment modalities are used.

Limitation of the study
This study failed to examine depression episodes across time. As a result, longitudinal research should be considered as a possible solution that allows seeing depression episodes across time after the commencement of ARV. The other limitation was related to the depression screening tool, which is not a diagnostic tool. Self-reported adherence measurement may introduce an overestimation of adherence secondary to social desirability and intentional recall bias. Similarly, risk of substance use and stigma assessment tools may also have social-desirability and intentional recall bias. Comorbidity is measured via self-reported whether a patient has confirmed diabetes mellitus, cardiovascular disease, hypertension, and cancer. This may undermine the proportion of comorbid cases.

Conclusions
This study revealed that there was a high prevalence of depression among HIV patients taking second-line antiretroviral therapy. Social support has a direct and indirect effect on depression. Perceived stigma mediates the effect of social support on depression. Having comorbid NCDs, uncontrolled viral load, substance use, and not-workable functional status were all found to be significant predictors of depression in PLHIV.

Abbreviations
ART: Antiretroviral therapy; PLHIV: People living with HIV; VL: Viral load; BMI: Body Mass Index; IQR: Interquartile range; SEM: Structural Equation Model; PHQ-9: Nine items patient health questionnaire; COVID-19: Coronavirus Disease 2019; NCD: Non-communicable disease (NCDs);

Acknowledgements
We acknowledge the Institutional Review Board (IRB) of Bahir Dar University’s College of Medicine and Health Science, School of Public Health, for providing timely ethical approval and unwavering support. We would also like to thank the managers and employees at all health facilities for allowing us to conduct the study, as well as the data collectors who gathered the data throughout the COVID 19 era.

Author contributions
SW and GD: Contributed to the conception and design of the work, and data analysis. AD and FA: wrote the main manuscript text, including figures and tables. Furthermore, all authors have agreed to the submitted journal and agree to be accountable for all aspects of the work. All authors read and approved the final manuscript.

Funding
This research was supported by Bahir Dar University College of Medicine and Health Science, School of Public Health. The funding body had no role in the design of the study, in the collection, analysis, and interpretation of data, and in writing the manuscript.

Availability of data and materials
The materials and datasets used and analyzed in the current study are available from the corresponding author upon reasonable request.

Declarations
Competing interests
The authors declare no competing interests.

Ethics approval and consent to participate
This research was carried out in line with the Helsinki Declaration. The Institutional Review Board (IRB) of Bahir Dar University’s College of Medicine and Health Science granted ethical approval with reference number 00224/2020. In addition, permission from facilities was acquired to use anonymized data. Furthermore, the confidentiality of the collected data was ensured by the use of code numbers rather than personal identification and the locking of the checklist. The purpose and significance of the study were explained to the participants, and each provided written informed consent before data was collected. Anonymous techniques were employed throughout the research process to keep data private.

Consent for publication
Not applicable.

Competing interests:
None of the authors has any competing interests.

Author details
1 School of Public Health, CMHS, Wollo University, Dessie, Ethiopia. 2 School of Public Health, CMHS, Bahir Dar University, Bahir Dar, Ethiopia. 3 Country Director, Nutrition International (NNI) in Ethiopia, Addis Ababa, Ethiopia.

Received: 12 January 2022  Accepted: 18 May 2022
Published online: 13 June 2022

References
1. UNAIDS. FACT SHEET 2021 global HIV statistics. End. AIDS epidemic, no. June, pp. 1–3, 2021.
2. Estill J, et al. The need for second-line antiretroviral therapy in adults in sub-Saharan Africa up to 2030: a mathematical modeling study. Lancet HIV. 2016;3(18):1–8.
3. Endalamaw A, Mekonnen M, Geremew D, Yehualashet FA, Tesera H, Habtewold TD. HIV/AIDS treatment failure and associated factors in Ethiopia: meta-analysis. BMC Public Health. 2020;20(82):1–12.
4. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. 2016.
5. Secretariat. HIV/AIDS and mental health: report by the, 2008.
6. World Federation for Mental Health. Depression : a global crisis. Companies, Int Trade Hum Rights, pp. 1–40, 2010.
7. Hailemariam S, Tessema B, Asfaw B, Gudeta M, Tadesse H, Tenkolu G. The prevalence of depression and associated factors in Ethiopia: findings from the National Health Survey. Int J Ment Health Syst. 2012;6(1):23. https://doi.org/10.1186/1752-4458-6-23.
8. Amare T, Getinet W, Shumet S, Asrat B. Prevalence and associated factors of depression among PLHIV in Ethiopia : systematic review and meta-analysis, 2017. Hindawi AIDS Res Treat. 2018;2018.9.
9. Chenneville T, Gabbidon K, Hanson P, Holyfield C. The impact of COVID-19 on HIV treatment and research: a call to action. Int J Environ Res Public Health. 2020;17(12):1–14.
10. Mi T, et al. Mental health problems of HIV healthcare providers during the COVID-19 Pandemic: the interactive effects of stressors and coping. AIDS Behav. 2021;25(1):18–27.
